Faith E. Davies

This study uses SCID-rab PDX models to analyze genomic and transcriptomic features of multiple myeloma, revealing selection of pre-existing high-risk clones.

This study analyzes whole-genome sequencing data from multiple myeloma patients to show that the timing of genetic events, not just their presence, affects clinical outcomes.

This paper develops a monobody-drug conjugate targeting mutant RAS in multiple myeloma, showing improved anti-tumor effects and safety in vitro and in vivo.

The paper investigates the mutagenic impact of radiotherapy in hematologic malignancies and finds that RT contributes to the ID8 mutational signature, which is associated with treatment resistance and relapse.